University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2
The purpose of this study is to obtain new knowledge regarding screening for COPD. This study will use a participant's cancer screening CT scans performed as part of routine health care among current and former smokers at risk for COPD to identify participants who have had a spirometry or will have a spirometry test as part of the study to verify COPD status.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Mar 25, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Observational
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Michigan
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Eligible for lung cancer screening by USPSTF 2021 criteria including age 50-80 years and currently or formerly smoking with at last 20 pack-years of smoking history at the time of consent.
- Willingness to participate in an observational clinical trial and to be contacted about future ancillary studies that could include interventional clinical trials.
- Ability to tolerate study procedures.
- Ability to provide informed consent.
- Clinical Lung Cancer Screening CT performed at the University of Michigan within the last year
- Meets one of the three following criteria: 1. Prior Diagnosis of COPD in the EMR 2. Prior pulmonary function meeting criteria for COPD (FEV1/FVC ≤ 0.70) or 3. LAA\>1% on lung cancer screening CT scan
- The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g. dyspnea or decreased exercise tolerance).
- Severe asthma, which is defined as any of the following: Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = \>250 fluticasone propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). The investigators will accept low-dose ICS/LABA or medium dose ICS. or 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months or One asthma hospitalization in the past 12 months
- Concurrent participation in a therapeutic trial where treatment is blinded.
- Active pregnancy. Documentation of birth control will be required for pre-menopausal women.
- Cognitive dysfunction that prevents the participant from completing study procedures.
- BMI \> 35 kg/m2 at baseline, due to the effects of body weight on CT scan quality.
- Current illicit substance abuse, including cannabis smoking.
- Any illness expected to cause mortality in the next 3 years.
- Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan quality.
- History of thoracic radiation or thoracic surgery with resection of lung tissue. Additional temporal
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of MichiganAnn Arbor, Michigan
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 25, 2026. Always confirm current availability with the study team.